After the long COVID-19 lockdown, Adial Pharmaceuticals (ADIL +0.7%) has launched its Latvia-based Phase 3 clinical trial, ONWARD, evaluating lead candidate AD04 (ondansetron) in people with alcohol use disorder (AUD).
Two Latvian sites would be active immediately while a third will be added shortly.
Ondansetron is a selective serotonin-3 antagonist.
It was originally marketed by GlaxoSmithKline for the treatment of
chemotherapy-induced nausea and vomiting.
Previously: Adial Pharma verifies companion diagnostic for substance abuse med AD04 (April 16)
https://seekingalpha.com/news/3583814-adial-pharma-on-go-late-stage-study-of-lead-drug-in-alcohol-use-disorder
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.